Literature DB >> 10881079

[Protective effect of benznidazole against parasite reactivation in patients chronically infected with Trypanosoma cruzi and treated with corticoids for associated diseases].

A Rassi1, V Amato Neto, A F de Siqueira, F Ferriolli Filho, V S Amato, A Rassi Júnior.   

Abstract

Patients in the chronic phase of Chagas' disease and receiving corticoid because of concommitant diseases were treated with benznidazole, which was initiated at the same time of the use of corticoid in a group of 12 patients or 15 days afterwards in 6 patients. It has been proved in another paper that in the chronic phase of Chagas' disease corticoid use is associated with increased parasitemia, as evaluated by xenodiagnosis. In this study benznidazole use prevented this increase, and we suggest that in immunocompromised patients with chronic Chagas' disease the use of this drug could be useful.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10881079     DOI: 10.1590/s0037-86821999000500002

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  11 in total

1.  Dexamethasone effects in the Strongyloides venezuelensis infection in a murine model.

Authors:  Eleuza R Machado; Daniela Carlos; Carlos A Sorgi; Simone G Ramos; Daniela I Souza; Edson G Soares; Julia M Costa-Cruz; Marlene T Ueta; David M Aronoff; Lúcia H Faccioli
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.

Authors:  Marcela L Ferraz; Ricardo T Gazzinelli; Rosana O Alves; Julio A Urbina; Alvaro J Romanha
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.

Authors:  María-Jesús Pinazo; Gerard Espinosa; Montserrat Gállego; Paulo Luis López-Chejade; Julio A Urbina; Joaquim Gascón
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

4.  Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.

Authors:  Paulo Marcos da Matta Guedes; Julio A Urbina; Marta de Lana; Luis C C Afonso; Vanja M Veloso; Washington L Tafuri; George L L Machado-Coelho; Egler Chiari; Maria Terezinha Bahia
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas' disease.

Authors:  Paulo M M Guedes; Fabiana S Oliveira; Fredy R S Gutierrez; Grace Kelly da Silva; Gerson Jhonatan Rodrigues; Lusiane Maria Bendhack; Douglas W Franco; Maria A Do Valle Matta; Dario S Zamboni; Roberto Santana da Silva; João Santana Silva
Journal:  Br J Pharmacol       Date:  2010-01-27       Impact factor: 8.739

6.  CHAGASIC MENINGOENCEPHALITIS IN AN HIV INFECTED PATIENT WITH MODERATE IMMUNOSUPPRESSION: PROLONGED SURVIVAL AND CHALLENGES IN THE HAART ERA.

Authors:  Renata Buccheri; Maria José Kassab; Vera Lucia Teixeira de Freitas; Sheila Cristina Vicente da Silva; Rita C Bezerra; Zarifa Khoury; Maria Aparecida Shikanai-Yasuda; José E Vidal
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-12       Impact factor: 1.846

7.  Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.

Authors:  Marcela L Ferraz; Ricardo T Gazzinelli; Rosana O Alves; Julio A Urbina; Alvaro J Romanha
Journal:  Antimicrob Agents Chemother       Date:  2008-11-10       Impact factor: 5.191

8.  Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with Trypanosoma cruzi antigens.

Authors:  Renato Sathler-Avelar; Danielle Marquete Vitelli-Avelar; Silvana Maria Elói-Santos; Eliane Dias Gontijo; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  BMC Infect Dis       Date:  2012-05-24       Impact factor: 3.090

Review 9.  Immunosuppression and Chagas disease: a management challenge.

Authors:  María-Jesús Pinazo; Gerard Espinosa; Cristina Cortes-Lletget; Elizabeth de Jesús Posada; Edelweiss Aldasoro; Inés Oliveira; Jose Muñoz; Montserrat Gállego; Joaquim Gascon
Journal:  PLoS Negl Trop Dis       Date:  2013-01-17

Review 10.  COVID-19: Implications for People with Chagas Disease.

Authors:  Ezequiel José Zaidel; Colin J Forsyth; Gabriel Novick; Rachel Marcus; Antonio Luiz P Ribeiro; Maria-Jesus Pinazo; Carlos A Morillo; Luis Eduardo Echeverría; Maria Aparecida Shikanai-Yasuda; Pierre Buekens; Pablo Perel; Sheba K Meymandi; Kate Ralston; Fausto Pinto; Sergio Sosa-Estani
Journal:  Glob Heart       Date:  2020-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.